Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines

被引:36
作者
Hurtubise, A
Momparler, RL
机构
[1] Hop St Justine, Ctr Rech Pediat, Montreal, PQ H3T 1C5, Canada
[2] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada
关键词
5-aza-2 '-deoxycytidine; antineoplastic activity; docetaxel; gene activation;
D O I
10.1097/01.cad.0000113334.52071.97
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antineoplastic activity of 5-aza-2-deoxycytidine (5-AZA-CdR) and docetaxel (Taxotere, Taxo) alone or in combination against human MDA-MB-231 breast, Calu-6 lung and DU-145 prostate carcinoma cell lines was evaluated by clonogenic assay. We also investigated by RTPCR the capacity of these agents to re-activate the expression of E-cadherin and maspin, two tumor suppressor genes that were silenced by DNA methylation. 5-AZA-CdR and Taxo in combination produced a greater loss of clonogenicity than either agent alone. In MDA-MB-231 breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and maspin genes by 5-AZA-CdR. These results provide a rationale for clinical trials on the combination of 5-AZA-CdR and Taxo in patients with advanced cancer.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 26 条
  • [1] Baylin SB, 1998, ADV CANCER RES, V72, P141
  • [2] BISSERY MC, 1991, CANCER RES, V51, P4845
  • [3] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
    Bruno, R
    Hille, D
    Riva, A
    Vivier, N
    Huinnink, WWTB
    van Oosterom, AT
    Kaye, SB
    Verweij, J
    Fossella, FV
    Valero, V
    Rigas, JR
    Seidman, AD
    Chevallier, B
    Fumoleau, P
    Burris, HA
    Ravclin, PM
    Sheiner, LB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 187 - 196
  • [4] Creane M, 1999, INT J RADIAT BIOL, V75, P725, DOI 10.1080/095530099140069
  • [5] Crown J, 1999, SEMIN ONCOL, V26, P5
  • [6] Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment
    Daskalakis, M
    Nguyen, TT
    Nguyen, C
    Guldberg, P
    Köhler, G
    Wijermans, P
    Jones, PA
    Lübbert, M
    [J]. BLOOD, 2002, 100 (08) : 2957 - 2964
  • [7] Docetaxel in non-small cell lung cancer: a review
    Davies, AM
    Lara, PN
    Mack, PC
    Gandara, DR
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 553 - 565
  • [8] Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO
  • [9] 2-5
  • [10] Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3σ, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells
    Gagnon, J
    Shaker, S
    Primeau, M
    Hurtubise, A
    Momparler, RL
    [J]. ANTI-CANCER DRUGS, 2003, 14 (03) : 193 - 202